F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Karyon Oy used to develop oral cancer targeted diagnostics and therapeutics. It was developing tissue specific targeting compounds for use in early diagnosis and therapy. The company was founded in 2001 and was located in Helsinki, Finland

Shanghai Longyao Biotech Co., Ltd. engages in the provision of health management services. It focuses on the innovative and development of biotechnology such as tumor immune cell technology,\nstem cell technology, cell storage technology, and anti-aging technology. Its business scope includes\ntechnology development, technical consulting, technology transfer, and technical services of biotechnology; and import and export of goods and technology. The company was founded on September 16, 2013 and is headquartered in Shanghai, China.,

Part of Halozyme Therapeutics, Inc., Halozyme, Inc. is an American company located in San Diego, CA, focused on biological products, except diagnostic substances.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Shanghai Jinmante Biotechnology Co., Ltd., established on 2012-06-05, Business scope includes licensed projects:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:In the field of biotechnology(remove human stem cells,Development and application of genetic diagnosis and treatment technology)technology development,technology transfer,technical consulting,Technical Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

Boji Biomedical Technology (Hangzhou) Co., Ltd., established on 2017-01-19, Business scope includes technology development,technology transfer,Technical Services,technical consulting:Biological Technology,medical technology,biological reagent,Chemical raw materials and products(Removal of hazardous chemicals and precursor chemicals);Sales:Chemical raw materials and products(Removal of hazardous chemicals and precursor chemicals).

Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company that has developed a proprietary oncolytic virus-based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy. GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccinia virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 is currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.

NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical\ncompany engaged in the discovery, development, manufacture and marketing of\nproprietary pharmaceutical products to treat life-threatening and other\nserious diseases. The firm was located in Boulder, CO.

Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.

Sanhome was one of the first group of companies which have been awarded GMP certificate in China. The company has been certificated as ‘state high-tech innovation enterprise’ by China Ministry of Science & Technology in 2003, has been ranked in top 100 pharmaceutical enterprises in China since 2009, and has been awarded ‘Top 100 pharmaceutical enterprises’ and ‘Top 50 pharmaceutical enterprises in growth’ by All-China Federation of Industry & Commerce in 2015.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA.

Access Pharmaceuticals (ACCP.ob) is an emerging pharmaceuticals company with a focus on oncology and diabetes. Access has one FDA approved treatment for oral mucositis (MuGard) which has been launched commercially in Europe and will be launched elsewhere in 2009. ProLindac, a novel DACH platinum chemotherapy, recently completed a Phase 2a trial in recurrent ovarian cancer and will enter combination trials shortly; ProLindac is partnered in the Far East and ACCP is actively seeking North American and European co-development partners. Additionally, ACCP has a novel nucleoside analogue, Thiarabine, which will enter Phase 2 leukemia trials this year, a preclinical stage monoclonal antibody (Angiolix) and additional preclinical oncology programs. Also, ACCP has an oral insulin and oral human growth hormone program which is being developed in a sponsored research agreement with a major pharmaceutical company (and for which ACCP is seeking additional development partnerships).

Bionoxx is a research and development company that develops immune regulation-based anticancer drugs to conquer cancer diseases.

Guangzhou Weirongte Pharmaceutical Technology Co., Ltd., established on 2015-01-16, Business scope includes natural science research and experimental development;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Import and export;Technology Import and Export

PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers. PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey.